s/hubermanlabPATENT LITIGATION•14h
19
votes
535
seen
Liquidia shares plunge 57% after YUTREPIA patent ruling
Liquidia’s YUTREPIA now faces a serious commercial threat after a Delaware court found two United Therapeutics patent claims valid and infringed. The ruling puts the product at risk even though the court has not decided damages or an injunction, and Liquidia plans to appeal while removing the PH-ILD indication from YUTREPIA’s label through an FDA supplement.
United Therapeutics is seeking a remedy that could restrict future sales. The parties must submit proposed judgment terms within one week, and PH-ILD represents roughly half of the inhaled treprostinil market. Liquidia shares fell 57%, wiping out roughly $3.6 billion in market value.
United Therapeutics is seeking a remedy that could restrict future sales. The parties must submit proposed judgment terms within one week, and PH-ILD represents roughly half of the inhaled treprostinil market. Liquidia shares fell 57%, wiping out roughly $3.6 billion in market value.
Timeline3
1d
The Delaware court issued its post-trial opinion in United Therapeutics v. Liquidia.
1d
Liquidia said it would appeal and submit an NDA supplement removing PH-ILD from YUTREPIA’s label.
1d
Liquidia shares closed down 57% after the infringement ruling.
1 comment
14h